JP2005506087A - プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用 - Google Patents
プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用 Download PDFInfo
- Publication number
- JP2005506087A JP2005506087A JP2003538376A JP2003538376A JP2005506087A JP 2005506087 A JP2005506087 A JP 2005506087A JP 2003538376 A JP2003538376 A JP 2003538376A JP 2003538376 A JP2003538376 A JP 2003538376A JP 2005506087 A JP2005506087 A JP 2005506087A
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- strand
- nucleotides
- viral
- helicase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001493065 dsRNA viruses Species 0.000 title claims abstract description 14
- 229920002477 rna polymer Polymers 0.000 title claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 title abstract description 4
- 230000003612 virological effect Effects 0.000 claims abstract description 38
- 230000000295 complement effect Effects 0.000 claims abstract description 18
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 108060004795 Methyltransferase Proteins 0.000 claims description 23
- 241000711549 Hepacivirus C Species 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- 239000003094 microcapsule Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002088 nanocapsule Substances 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 108010076039 Polyproteins Proteins 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 108020000999 Viral RNA Proteins 0.000 claims description 7
- 210000000234 capsid Anatomy 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 16
- 238000001890 transfection Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 6
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000009341 RNA Virus Infections Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100025458 Inosine triphosphate pyrophosphatase Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155280 | 2001-10-26 | ||
| DE10158411 | 2001-11-29 | ||
| DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
| PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
| DE10235621 | 2002-08-02 | ||
| PCT/EP2002/011973 WO2003035876A1 (de) | 2001-10-26 | 2002-10-25 | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506087A true JP2005506087A (ja) | 2005-03-03 |
| JP2005506087A5 JP2005506087A5 (enExample) | 2006-01-05 |
Family
ID=34799649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538376A Withdrawn JP2005506087A (ja) | 2001-10-26 | 2002-10-25 | プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20040248835A1 (enExample) |
| JP (1) | JP2005506087A (enExample) |
| CN (1) | CN1608133A (enExample) |
| WO (1) | WO2003035876A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| SI1407044T2 (en) * | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| CN105622756B (zh) | 2007-08-02 | 2020-07-28 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| US8431692B2 (en) * | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CN102405286A (zh) | 2008-09-22 | 2012-04-04 | 阿克赛医药公司 | 减小大小的自递送RNAi化合物 |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| SG174367A1 (en) | 2009-03-23 | 2011-10-28 | Quark Pharmaceuticals Inc | Compounds compositions and methods of treating cancer and fibrotic diseases |
| EP2467169A4 (en) * | 2009-08-21 | 2013-01-02 | Gilead Biologics Inc | IN VIVO SCREENING ASSAYS |
| BR112012008054A2 (pt) | 2009-08-21 | 2017-05-23 | Gilead Biologics Inc | domínios catalíticos de lisil oxidase e loxl2 |
| EP2467162A4 (en) * | 2009-08-21 | 2013-10-02 | Gilead Biologics Inc | THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| CN102713601A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 体外筛选试验 |
| SG183174A1 (en) | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
| KR101852210B1 (ko) | 2010-03-24 | 2018-04-25 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| EP2550001B1 (en) | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| WO2012053741A2 (ko) | 2010-10-22 | 2012-04-26 | 성균관대학교산학협력단 | Rna 간섭을 유도하는 핵산 분자 및 그 용도 |
| ES2716818T3 (es) | 2012-05-22 | 2019-06-17 | Olix Pharmaceuticals Inc | Molécula de ácido nucleico inductora de interferencias de arn capaz de penetrar en las células y uso de la misma |
| PL3466432T3 (pl) | 2014-05-15 | 2021-02-08 | Insmed Incorporated | Sposoby leczenia zakażeń płuc niegruźliczymi mykobakteriami |
| EP3235906B1 (en) | 2014-12-15 | 2021-06-23 | Bonac Corporation | Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression |
| WO2017085550A1 (en) | 2015-11-16 | 2017-05-26 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| CA3022877A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb |
| KR102825946B1 (ko) | 2016-02-02 | 2025-06-27 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
| KR102339886B1 (ko) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| JP7424728B2 (ja) | 2017-02-10 | 2024-01-30 | オリック パルマセゥティカルズ インコーポレイテッド | Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999062927A1 (en) * | 1998-06-05 | 1999-12-09 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| KR101215789B1 (ko) * | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| SI1407044T2 (en) * | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
-
2002
- 2002-10-25 WO PCT/EP2002/011973 patent/WO2003035876A1/de not_active Ceased
- 2002-10-25 US US10/493,768 patent/US20040248835A1/en not_active Abandoned
- 2002-10-25 US US10/493,686 patent/US20050119202A1/en not_active Abandoned
- 2002-10-25 CN CNA02826181XA patent/CN1608133A/zh active Pending
- 2002-10-25 JP JP2003538376A patent/JP2005506087A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20050119202A1 (en) | 2005-06-02 |
| US20040248835A1 (en) | 2004-12-09 |
| WO2003035876A1 (de) | 2003-05-01 |
| CN1608133A (zh) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506087A (ja) | プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用 | |
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| EP0546092B1 (en) | Therapeutic ribozyme compositions | |
| US6107027A (en) | Ribozymes for treating hepatitis C | |
| JP4209678B2 (ja) | 標的遺伝子の発現を阻害する方法および腫瘍を治療するための医薬 | |
| US9255268B2 (en) | Methods for diagnosing and treating learning or mental disorders | |
| RU2733361C1 (ru) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией | |
| JP2005512976A (ja) | Ｒｎａ干渉により線維化疾患を処置するための医薬 | |
| WO2002046449A2 (en) | Selection of catalytic nucleic acids targeted to infectious agents | |
| JPH06501841A (ja) | サイトメガウイルス感染の作用を変調するオリゴヌクレオチド | |
| JP2010029212A (ja) | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
| US9198927B2 (en) | Targeting opposite strand replication intermediates of single-stranded viruses by RNAI | |
| Leaman et al. | Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense | |
| Muasya et al. | Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya | |
| KR101384860B1 (ko) | 표적 물질 특이적으로 ｓｉＲＮＡ를 방출하는 ＲＮＡ 간섭용 조성물 및 이를 이용한 ＨＣＶ 관련 질환 치료용 조성물 | |
| WO2018145009A1 (en) | Dna-zyme based methods & compositions for treating huntington's disease | |
| EP1438409A1 (de) | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus | |
| AU2002228756B2 (en) | Selection of catalytic nucleic acids targeted to infectious agents | |
| Yao et al. | Biodistribution and pharmacokinetics of antisense phosphorothioate oligodeoxynucleotide in mice | |
| JP2013223426A (ja) | Ｒｒｍ２のアンタゴニストを有効成分として含有するｃ型肝炎治療剤 | |
| AU2002228756A1 (en) | Selection of catalytic nucleic acids targeted to infectious agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051025 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071004 |